CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Rhea-AI Summary
CytomX (NASDAQ: CTMX) expanded its strategic research and licensing collaboration with Regeneron to develop conditionally activated bispecific cancer therapies using PROBODY and Veloci-Bi platforms.
CytomX will receive a $37 million target nomination payment, with total potential milestones of up to approximately $4 billion and tiered royalties, while Regeneron funds preclinical, clinical and commercialization activities.
Positive
- CytomX to receive immediate $37 million target nomination payment for two additional programs
- Total potential collaboration payments could reach approximately $4 billion in milestones
- Regeneron responsible for funding preclinical, clinical development and commercialization activities
- Regeneron option to select up to six additional future targets, expanding program scope
- CytomX eligible for tiered global net sales royalties on collaboration products
Negative
- None.
News Market Reaction – CTMX
In the Jun 3 session, CTMX gained 1.90%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.5% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Investor conferences update | Neutral | +1.1% | Announced participation in two June 2026 healthcare investor conferences. |
| May 18 | Regulatory hire | Positive | -3.0% | Appointed new SVP of Regulatory Affairs to lead global regulatory strategy. |
| May 07 | Q1 2026 earnings | Negative | -0.5% | Reported lower revenue versus Q1 2025 and a return to net loss. |
| Apr 30 | Earnings date notice | Neutral | +4.2% | Set date and webcast details for Q1 2026 financial results call. |
| Mar 17 | Equity offering | Negative | -19.3% | Priced $250M common stock and pre-funded warrant offering to fund pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often aligns with price moves; capital-raising and earnings headlines saw negative reactions, while neutral scheduling news skewed modestly positive. A single leadership appointment drew a negative divergence.
Over the last few months, CytomX has reported Q1 2026 results with revenue of $10.3M versus $50.9M in Q1 2025 and executed a $250M equity offering on March 19, 2026. That financing was followed by a -19.27% reaction. Subsequent items included earnings-date logistics and June conference participation, which had small positive moves, and a senior regulatory hire with a modest negative reaction. Today’s expanded Regeneron collaboration builds on those prior collaboration and capital-raising themes.
Key Terms
bispecific immunotherapies medical
bispecific antibodies medical
tumor microenvironment medical
proteases medical
T-cell engaging therapies medical
preclinical technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -
- CytomX to receive
- Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately ~
SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals, Inc. to create conditionally-activated bispecific cancer therapies utilizing CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.
The Regeneron and CytomX collaboration, initially entered into in 2022, is strategically focused on applying CytomX’s biologic masking strategies in combination with Regeneron’s bispecific antibodies to develop investigational bispecifics that remain inactive until activated by proteases in the tumor microenvironment. This technology has the potential to widen the therapeutic window and help minimize off-target effects for next-generation T-cell engaging therapies, potentially addressing tumor types that have historically been challenging for immunotherapy.
“Cancer necessitates innovative treatment approaches, and with this expanded collaboration with CytomX, we are advancing bispecific treatments where we see the most promise. Our complementary oncology expertise with CytomX – including application of our proprietary VelociSuite® technologies developed to accelerate drug discovery and development – make us uniquely suited to work together on this endeavor to bring new medicines to patients in need,” said John Lin, M.D., Ph.D., Senior Vice President of Oncology & Antibody Technology Research at Regeneron.
“Our ongoing research collaboration with Regeneron is based on a shared commitment to cutting edge science and a vision to push the boundaries of cancer immunotherapy. At CytomX, we are applying our deep understanding of masking and protease biology to unlock new opportunities uniquely enabled by our technology,” said Sean McCarthy, D. Phil, CEO and Chairman of CytomX. “Regeneron’s deep expertise in bispecific immunotherapies has made them an ideal partner in expanding the reach of the PROBODY platform, and we look forward to building on our alliance momentum to collectively make a meaningful difference for people with cancer.”
Under the expanded agreement, Regeneron and CytomX will continue to collaborate on discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development and commercialization activities. CytomX will receive a target nomination payment of
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond CytomX’s control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements and projected cash runway. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, including varsetatug masetecan (Varseta-M) and CX-801, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX's planned interactions with the U.S. Food and Drug Administration and the ability to align on a potential registrational study design and regulatory pathway for Varseta-M, CytomX’s or its collaborative partners’ ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of Varseta-M and CX-801 and the timing of initial and ongoing data availability for CytomX’s clinical trials, including Varseta-M and CX-801, and other development milestones. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology; uncertainties around the Company’s ability to raise sufficient funds to carry out its planned research and development; CytomX’s clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials, including initial Varseta-M clinical trial results, may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX’s dependence on the success of Varseta-M and CX-801; CytomX’s reliance on third parties for the manufacture of the Company’s product candidates; possible regulatory developments in the United States and foreign countries, including China and the European Union; and the risk that we may incur higher costs than expected for research and development. Additional applicable risks and uncertainties include those relating to CytomX’s preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other trademarks are the properties of their respective owners.
| CytomX Contacts: Chris Ogden SVP, Chief Financial Officer cogden@cytomx.com Investor Contact: Precision AQ Stephanie Ascher Stephanie.Ascher@precisionaq.com Media Contact: Precision AQ Colleen Ketchum Colleen.ketchum@precisionaq.com |
